News
March 19, 2025
Investor
Supplementary Materials of Consolidated Financial Results for the Six Months Ended January 3 
March 13, 2025
Investor
(Delayed)Summary of Consolidated Financial Results for the Six Months Ended January 31, 2025 (Based on Japanese GAAP)
February 12, 2025
Research and Development
The establishment of World's first "CADASIL Drug Discovery Research Department" in collaboration with National Cerebral and Cardiovascular Center
December 13, 2024
Investor
(Delayed)Summary of Consolidated Financial Results for the Three Months Ended October 31, 2024 (Based on Japanese GAAP)
September 30, 2024
Investor
Notice of the 27th Annual General Meeting of Shareholders
September 27, 2024
Investor
(Delayed) Summary of Consolidated Financial Results for the Year Ended July 31, 2024 (Based on Japanese GAAP)
June 28, 2024
Investor
A milestone has been achieved as set forth in an Exclusive Licensing Agreement between PFI and Mitsubishi Tanabe Pharma Corporation for a New Investigational Therapeutic Antibody for autoimmune diseases
June 11, 2024
Investor
(Delayed)Summary of Consolidated Financial Results for the Nine Months Ended April 30, 2024 (Based on Japanese GAAP)
May 28, 2024
Investor
Company Research And Analysis Report（FISCO）
March 15, 2024
Investor
(Delayed)Summary of Consolidated Financial Results for the Six Months Ended January 31, 2024 (Based on Japanese GAAP)
March 13, 2025
Investor
(Delayed)Summary of Consolidated Financial Results for the Six Months Ended January 31, 2025 (Based on Japanese GAAP)
February 12, 2025
Research and Development
The establishment of World's first "CADASIL Drug Discovery Research Department" in collaboration with National Cerebral and Cardiovascular Center
December 13, 2024
Investor
(Delayed)Summary of Consolidated Financial Results for the Three Months Ended October 31, 2024 (Based on Japanese GAAP)
September 30, 2024
Investor
Notice of the 27th Annual General Meeting of Shareholders
September 27, 2024
Investor
(Delayed) Summary of Consolidated Financial Results for the Year Ended July 31, 2024 (Based on Japanese GAAP)
June 28, 2024
Investor
A milestone has been achieved as set forth in an Exclusive Licensing Agreement between PFI and Mitsubishi Tanabe Pharma Corporation for a New Investigational Therapeutic Antibody for autoimmune diseases
June 11, 2024
Investor
(Delayed)Summary of Consolidated Financial Results for the Nine Months Ended April 30, 2024 (Based on Japanese GAAP)
May 28, 2024
Investor
Company Research And Analysis Report（FISCO）
March 15, 2024
Investor
(Delayed)Summary of Consolidated Financial Results for the Six Months Ended January 31, 2024 (Based on Japanese GAAP)